Bell Potter update
some snips
"Remarkable response rate ~5x higher than historical levels
IMM have released exceptional initial data from the single-arm cohort of the Phase 2b
trial in first-line head & neck squamous cell carcinoma (1L HNSCC). Data was from 26
evaluable patients with CPS<1, who were treated with Efti + pembrolizumab. The
clear standout is a remarkable 27% of patients (=7/26) achieved an Overall
Response Rate (ORR), meaning their tumour(s) shrank by at least 30%. To put this
into context, first-line pembro monotherapy is not approved for these patients as they
historically only achieve a meagre ORR of ~5%. Hence this data indicates patients are
achieving a ~5-fold higher rate of tumour response when Efti is added to pembro
compared to historical results in a similar patient group (27% vs. 5%). Even if we
assume the remaining 7 subjects still to be evaluated do not achieve a response, the
ORR would be 21% (=7/33), or ~4x the historical rate of ~5% for pembro monotherapy"
"Investment view: Maintain BUY (spec.); $0.80 valuation
These exceptional results further exemplify Efti’s ability to boost the immune system
and enhance responses to PD-1 immunotherapy, even in patients with low/no PD-L1
expression. Our confidence in a positive Part A read out is further increased off the
back of this data. We of course acknowledge the limitations but necessity of cross-trial
comparisons for single-arm data readouts, and this is why we are particularly excited
for the upcoming readout from Cohort A of this Phase 2b trial. Cohort A will be the first
randomised head-to-head data of Efti + pembro against pembro alone. The first data
from Cohort A, including the ORR primary endpoint, is expected in the current Q2
quarter, a major near-term catalyst for IMM. We have increased our PoS (%)
assumptions in 1L HNSCC after this data release. We maintain our Buy (speculative)
recommendation and increase our valuation to $0.80 (from $0.65)"
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-740
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
39.8¢ |
Change
-0.033(7.56%) |
Mkt cap ! $472.5M |
Open | High | Low | Value | Volume |
40.5¢ | 41.0¢ | 39.5¢ | $1.586M | 3.964M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 426611 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 157979 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 426611 | 0.395 |
16 | 407994 | 0.390 |
12 | 210595 | 0.385 |
19 | 433004 | 0.380 |
8 | 547578 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 161839 | 9 |
0.405 | 104153 | 8 |
0.410 | 35276 | 4 |
0.415 | 142009 | 7 |
0.420 | 35159 | 2 |
Last trade - 12.37pm 12/06/2024 (20 minute delay) ? |
|
|||||
Last
40.0¢ |
  |
Change
-0.033 ( 5.88 %) |
|||
Open | High | Low | Volume | ||
41.0¢ | 41.0¢ | 39.5¢ | 1172822 | ||
Last updated 12.54pm 12/06/2024 ? |
Featured News
IMM (ASX) Chart |